Clinical trials and research studies

The primary objective of this study is to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing at least a 50% reduction in baseline depressive symptom severity, based on Montgomery Åsberg Depression Rating Scale (MADRS) total score, at 12 months from randomization.

PURPOSE: This is a biological sample collection study aimed at developing an early diagnostic tool for endometrial and ovarian cancer. The investigators are studying the relationship between estrogen driven gynecological cancers, inflammation and the microbiome. Patients who have been diagnosed with endometrial cancer or undergo presurgical evaluation for suspicion of ovarian cancer who are scheduled for a hysterectomy, bilateral oophorectomy and/or salpingectomy are eligible. Control patients undergoing gynecological surgery for benign indications are also being recruited.

CT-155-R-001: The purpose of this study is to investigate if digital therapeutics (a moblie software application) can help treat certain symptoms of schizophrenia. 

To evaluate the efficacy and safety of CT-155 in reducing experiential negative symptoms, compared with a Digital Control, in adult and late adolescent participants diagnosed with schizophrenia.

AOA DX is developing a blood test to detect ovarian cancer (biomarker).  The purpose of this study is to collect and store donated blood samples and associated medical data from participating subjects to help develop the ovarian cancer test.

PURPOSE: Endometriosis is an inflammatory disorder in which the tissue that lines the inside of the uterus (the endometrium) spreads to the pelvic and peritoneal cavities outside of the uterus. This is a biological sample collection study examining how bacteria located within the vagina, the urogenital tract and the gastrointestinal tract may affect the development of endometriosis. Investigators are also exploring how an individual’s microbiome affects their estrogen metabolism and inflammation.

TV50717-CNS-40223: The purpose of this study is to get a better understanding of the disease course of tardive dyskinesia and the impact it has on individuals’ lives. In subjects who may begin on deutetrabenazine (AUSTEDO®) treatment during the study, it will also help investigate the real-world effectiveness of this treatment, particularly on a person’s quality of life.

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.

PURPOSE: The purpose of this clinical trial is to find out if the investigational study treatment, called inclisiran, can help prevent cardiovascular events (such as heart attacks, strokes, and cardiovascular-related deaths) in adults who already have been diagnosed with cardiovascular disease